Dublin, Sept. 13, 2017 -- The "Diabetes Insulin Pen Market Outlook 2022: Top 5 European Countries Opportunity and Demand Analysis, Market Forecast 2017 - 2022" report has been added to Research and Markets' offering.
Diabetes Insulin Pen Market Outlook 2022: Top 5 European Countries Opportunity and Demand Analysis, Market Forecast 2017-2022 examines the market, demand, competitive landscape and trends of the top 5 European markets of the insulin pen market. It provides an all-round analysis of overall number of patients with diabetes and insulin users. It offers information on users of insulin pens, specifically focusing on reusable and prefilled insulin pen users. Market outlook in value terms for the forecasted period for insulin pen market has been detailed in the report. The report also explores detailed description of growth drivers and barriers of the insulin pen market.
Market growth can be attributed to factors such as increasing number of patients with diabetes, high adoption rate, user-friendly design, surging popularity amid consumers, help avoid over/under-dosing of insulin, rising market demand for human insulin analogs, government support and technological advancements in the field of insulin pen devices.
The report concludes with the profiles of major players in the insulin pen market such as Novo Nordisk, Eli Lilly, Sanofi, Owen Mumford and Ypsomed. The major market players are evaluated on various parameters such as company overview, product outlook and latest development and trends of the insulin pen market.
Long-term Growth Projection and Development:
- Prefilled (Disposable) insulin pen grasps the dominant share in the top 5 European countries insulin pen market
- In 2016, there were over 7,800 Thousand users of insulin pen in the top 5 European countries
- Germany insulin pen market generated more than US$ 1.5 Billion in 2016
- Spain has shown its potential to become leading #2 market with around 20% market share in 2016
Top 5 European Countries Covered in the Report Have Studied from 8 Viewpoints:
1. Overall Diabetes Population (2011 - 2022)
2. Insulin Users (2011 - 2022)
3. Insulin Pen Users (2011 - 2022)
4. Reusable (Cartridge) Insulin Pen Users (2011 - 2022)
5. Prefilled (Disposable) Insulin Pen Users (2011 - 2022)
6. Insulin Pen Market (2011 - 2022)
7. Reusable (Cartridge) Insulin Pen Market (2011 - 2022)
8. Prefilled (Disposable) Insulin Pen Market (2011 - 2022)
Top 5 European Countries Covered in the Report are as follows:
1. United Kingdom
2. France
3. Italy
4. Spain
5. Germany
Key Companies Covered in the Report are as follows:
1. Novo Nordisk
2. Eli Lilly
3. Sanofi
4. Owen Mumford
5. Ypsomed
For more information about this report visit https://www.researchandmarkets.com/research/8jmzmh/diabetes_insulin
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diabetes Devices


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Italy Fines Apple €98.6 Million Over App Store Dominance
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 



